Arrowhead Pharmaceuticals, Inc. (ARWR) — closed signal from February 16, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 17, 2026.
Predicted vs. what happened
What happened
Reached its target in 78 days.
The thesis — published February 16, 2026
Arrowhead is a short-term, news-driven biotech that can move a lot. Recent positives: an early US launch of REDEMPLO showing initial prescriptions and a $1.33 billion financing that eases near-term funding pressure. Together these shift the story toward how well the launch performs, not just cash worries. Because the stock has been volatile, treat any position as a smaller, staged trade and watch launch metrics closely-poor launch news could cause big down moves.
Primary drivers
- REDEMPLO early script growth could surprise on the upside
- Large financing eases near-term funding pressure
- Biotech news can quickly move the stock both ways, so stage buys
- Adding this helps healthcare exposure if other sectors wobble
How it played out
ARWR: target reached in 78 days
Lyra published ARWR at $63.82 on February 16, 2026, with expected growth of 22%. The thesis pointed to REDEMPLO early prescription growth, a $1.33 billion financing that eased near-term funding pressure, biotech news volatility, and added healthcare exposure if other sectors wobbled.
Inside the window, ARWR rose to a peak of $82 on May 14, 2026. That was above the $77.86 target, and the target was reached in 78 days. The peak gain was 28.5%. By May 17, 2026, it ended at $76.67. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.